Otic Pharma
Foam-based Products for the Treatment of Ear, Nose, and Throat Disorders
Company Overview
Snapshot
Founded in January 2008, Otic Pharma operated with 1-10 employees. The company raised $5.25 million across 4 funding rounds from 5 investors. A significant milestone for the company was its acquisition by Novus Therapeutics in May 2017.
Business overview
Otic Pharma Ltd develops therapeutic products for ear, nose, and throat (ENT) disorders, leveraging its proprietary FoamOtic platform. This technology enables sustained drug exposure, fewer administrations, and lower doses for conditions like acute otitis externa (AOE, or "swimmer's ear"). The company's product pipeline included FoamOtic Externa, FoamOtic Sinus for chronic sinusitis, Foam-O-Vet for otitis externa in dogs. Otic Pharma operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drug Delivery for the healthcare and life sciences markets.
Strategic signal
In May 2017, Otic Pharma completed its merger with Tokai Pharmaceuticals, which subsequently changed its name to Novus Therapeutics. This acquisition provided Novus Therapeutics with approximately $30 million in cash to accelerate the development of its product candidates, including Otic Pharma's foam-based drug delivery technology platform. This event signaled a strategic consolidation in the ENT pharmaceutical market, validating Otic Pharma's technology and providing a clear exit for investors while positioning the combined entity for further growth in addressing ear, nose, and sinus conditions.
Log in to access full profile ›Company Intelligence Q&A
- What was a key strategic event for Otic Pharma in 2017?
- In May 2017, Otic Pharma completed its merger with Tokai Pharmaceuticals, which subsequently changed its name to Novus Therapeutics. This acquisition led to Otic Pharma's inactive status.
- Which investors participated in Otic Pharma's May 2015 funding round?
- In May 2015, Otic Pharma received funding from investors including OrbiMed and Pontifax.
- What was the outcome of the Phase 2 trial for FoamOtic Externa?
- In January 2015, Otic Pharma announced positive results from a Phase 2 trial of FoamOtic Externa, a once-a-day, single antibiotic, steroid-free product for Acute Otitis Externa (AOE).
- Which investor led Otic Pharma's June 2009 funding round?
- In June 2009, Otic Pharma secured funding led by. This funding round was a significant step for the company's early development.
- What was the purpose of the $4.3 million investment in Otic Pharma in February 2012?
- In February 2012, OrbiMed invested $4.3 million in Otic Pharma to support the company's clinical trials and the development of veterinary treatments for ear diseases.